Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$2.16B |
| 2 |
Hershey
HSY
|
+$663M |
| 3 |
Lockheed Martin
LMT
|
+$622M |
| 4 |
Altria Group
MO
|
+$525M |
| 5 |
Pfizer
PFE
|
+$499M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$2.76B |
| 2 |
Merck
MRK
|
+$2.35B |
| 3 |
Automatic Data Processing
ADP
|
+$1.57B |
| 4 |
Blackstone
BX
|
+$1.38B |
| 5 |
Illinois Tool Works
ITW
|
+$1.13B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.85% |
| 2 | Financials | 12.71% |
| 3 | Healthcare | 11.72% |
| 4 | Consumer Discretionary | 10.09% |
| 5 | Industrials | 9.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1826
Protolabs
PRLB
$1.92B
| $13.6M | ﹤0.01% |
380,016
+4,904
| +1% | +$177K |
|
1827
ANI Pharmaceuticals
ANIP
$1.8B
| $13.6M | ﹤0.01% |
196,483
+49,431
| +34% | +$2.98M |
|
1828
Ardelyx
ARDX
$1.23B
| $13.5M | ﹤0.01% |
1,853,827
+37,095
| +2% | +$317K |
|
1829
Flex
FLEX
$42.6B
| $13.5M | ﹤0.01% |
471,028
-182,859
| -28% | -$4.8M |
|
1830
Agilon Health
AGL
$1.6B
| $13.5M | ﹤0.01% |
88,273
+14,407
| +20% | +$2.4M |
|
|
ALPN
1831
DELISTED
Alpine Immune Sciences Inc
ALPN
| $13.4M | ﹤0.01% |
339,142
+41,690
| +14% | +$1.23M |
|
1832
IonQ
IONQ
$14.9B
| $13.4M | ﹤0.01% |
1,345,395
+24,120
| +2% | +$258K |
|
1833
nCino
NCNO
$2.1B
| $13.4M | ﹤0.01% |
359,402
+12,344
| +4% | +$389K |
|
|
RC
1834
Ready Capital
RC
$274M
| $13.4M | ﹤0.01% |
1,467,288
+167,021
| +13% | +$1.55M |
|
|
DVAX
1835
DELISTED
Dynavax Technologies
DVAX
| $13.4M | ﹤0.01% |
1,078,871
+14,869
| +1% | +$194K |
|
1836
SiTime
SITM
$16.5B
| $13.3M | ﹤0.01% |
142,914
+475
| +0.3% | +$50K |
|
|
UMH
1837
UMH Properties
UMH
$1.29B
| $13.3M | ﹤0.01% |
818,120
+17,551
| +2% | +$269K |
|
1838
TriCo Bancshares
TCBK
$1.86B
| $13.2M | ﹤0.01% |
360,202
+17,783
| +5% | +$647K |
|
1839
Collegium Pharmaceutical
COLL
$1.14B
| $13.2M | ﹤0.01% |
340,433
+34,967
| +11% | +$1.22M |
|
1840
Helios Technologies
HLIO
$2.63B
| $13.2M | ﹤0.01% |
295,565
+36,583
| +14% | +$1.57M |
|
1841
Shutterstock
SSTK
$217M
| $13.2M | ﹤0.01% |
287,691
+962
| +0.3% | +$45.8K |
|
1842
Appian
APPN
$2.03B
| $13.2M | ﹤0.01% |
329,601
+4,313
| +1% | +$150K |
|
1843
Dyne Therapeutics
DYN
$4.68B
| $13.1M | ﹤0.01% |
461,522
+129,954
| +39% | +$2.94M |
|
|
AKRO
1844
DELISTED
Akero Therapeutics
AKRO
| $13.1M | ﹤0.01% |
518,286
+92,741
| +22% | +$2.23M |
|
1845
Shenandoah Telecom
SHEN
$690M
| $13M | ﹤0.01% |
750,400
-1,515
| -0.2% | -$29.4K |
|
1846
Dutch Bros
BROS
$9.14B
| $13M | ﹤0.01% |
393,938
+96,999
| +33% | +$2.86M |
|
1847
Goosehead Insurance
GSHD
$2.3B
| $13M | ﹤0.01% |
195,030
+4,480
| +2% | +$342K |
|
1848
Liberty Latin America Class C
LILAK
$1.66B
| $13M | ﹤0.01% |
2,039,233
-2,095,024
| -51% | -$13M |
|
1849
Harmonic Inc
HLIT
$1.27B
| $12.9M | ﹤0.01% |
960,392
+36,519
| +4% | +$466K |
|
1850
Eagle Bancorp
EGBN
$847M
| $12.9M | ﹤0.01% |
549,347
+52,264
| +11% | +$1.3M |
|
Similar funds
Charles Schwab's Q1 2024 Portfolio in Review
As of Q1 2024, Charles Schwab held 3,573 positions worth $433B, up 10% from $394B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Trading was light in Q1 2024: portfolio turnover was 3.8%. Charles Schwab opened 35 new positions and exited 102, leaving the 3,573-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 23% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q1 2024 buy was Schwab Fundamental US Large Company Index ETF: 3,608,604 shares worth $81.1M.
- Charles Schwab added most to Bristol-Myers Squibb in Q1 2024, an estimated $2.16B increase.
- Charles Schwab's biggest Q1 2024 reduction was Broadcom, cutting an estimated $2.76B.
- Charles Schwab fully exited Splunk Inc in Q1 2024, selling an estimated $104M.
- Charles Schwab's ten largest holdings make up 20% of its $433B portfolio in Q1 2024.
- Charles Schwab opened 35 new positions and closed 102 in Q1 2024.
- Charles Schwab's portfolio value rose 10% quarter-over-quarter to $433B.
Based on Charles Schwab's 13F filing for Q1 2024, filed 9 May 2024.